| Literature DB >> 23533613 |
Hee Jung Yang1, Namshin Kim, Ki Moon Seong, HyeSook Youn, BuHyun Youn.
Abstract
Radioresistance is a main impediment to effective radiotherapy for non-small cell lung cancer (NSCLC). Despite several experimental and clinical studies of resistance to radiation, the precise mechanism of radioresistance in NSCLC cells and tissues still remains unclear. This result could be explained by limitation of previous researches such as a partial understanding of the cellular radioresistance mechanism at a single molecule level. In this study, we aimed to investigate extensive radiation responses in radioresistant NSCLC cells and to identify radioresistance-associating factors. For the first time, using RNA-seq, a massive sequencing-based approach, we examined whole-transcriptome alteration in radioresistant NSCLC A549 cells under irradiation, and verified significant radiation-altered genes and their chromosome distribution patterns. Also, bioinformatic approaches (GO analysis and IPA) were performed to characterize the radiation responses in radioresistant A549 cells. We found that epithelial-mesenchymal transition (EMT), migration and inflammatory processes could be meaningfully related to regulation of radiation responses in radioresistant A549 cells. Based on the results of bioinformatic analysis for the radiation-induced transcriptome alteration, we selected seven significant radiation-altered genes (SESN2, FN1, TRAF4, CDKN1A, COX-2, DDB2 and FDXR) and then compared radiation effects in two types of NSCLC cells with different radiosensitivity (radioresistant A549 cells and radiosensitive NCI-H460 cells). Interestingly, under irradiation, COX-2 showed the most significant difference in mRNA and protein expression between A549 and NCI-H460 cells. IR-induced increase of COX-2 expression was appeared only in radioresistant A549 cells. Collectively, we suggest that COX-2 (also known as prostaglandin-endoperoxide synthase 2 (PTGS2)) could have possibility as a putative biomarker for radioresistance in NSCLC cells.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23533613 PMCID: PMC3606344 DOI: 10.1371/journal.pone.0059319
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Primer pairs of real-time RT-PCR analysis.
| Gene | Gene name | Primers from 5′ to 3′ | Size (bp) |
| SESN2 | Sestrin 2 | F: | 101 |
| R: | |||
| FN1 | Fibronectin 1 | F: | 259 |
| R: | |||
| TRAF4 | Tumor necrosis factor (TNF) | F: | 317 |
| receptor-associated factor 4 | R: | ||
| CDKN1A | Cyclin-dependent kinase inhibitor 1, p21 | F: | 90 |
| R: | |||
| COX-2 | Cyclooxygenase 2, | F: | 305 |
| Prostaglandin-endoperoxide synthase 2 (PTGS2) | R: | ||
| DDB2 | DNA damage binding protein 2 | F: | 132 |
| R: | |||
| FDXR | Ferredoxin reductase | F: | 366 |
| R: | |||
| GAPDH | Glyceraldehyde-3-phosphate | F: | 177 |
| dehydrogenase | R: |
Figure 1Design of RNA-seq study in radioresistant NSCLC A549 cells.
(A) Determination of appropriate irradiation condition based on expression of representative radioresponsive proteins. (B) A schematic diagram for design and goals of our study. TopHat aligns RNA-seq reads to genome reference (hg19) and finds transcript splice sites. Cufflinks assemble the reads generated from TopHat alignment into transcripts. Cufflinks package consists of the following software - Cufflinks, assembles transcrips; Cuffcompare, compares transcript assemblies to annotation; Cuffdiff, finds differentially expressed genes and transcripts.
Figure 2Chromosome distribution patterns of differentially expressed genes of radioresistant A549 cells in response to IR.
(x-axis: chromosome coordinate, y-axis: the number of differentially expressed genes of A549 cells under irradiation in 400 kb sliding window).
GO category enrichment profile of radioresistant A549 cells in response to IR (p-value<0.01).
| GO ID | Enriched significant GO category | p-value | Significant gene symbols | ||
|
| |||||
| GO:0007172 | Signal complex assembly | 4.20E−08 | MAPK8IP2, PTK2 | ||
| GO:0051647 | Nucleus localization | 4.65E−08 | CDC42, PTK2 | ||
| GO:0006427 | Histidyl-tRNA aminoacylation | 6.82E−07 | HARS2 | ||
| GO:0007179 | Transforming growth factor beta (TGF-β) receptor signaling pathway | 1.69E−06 | ACVR1, FURIN, GDF15, ID1, SMAD1, TGFBR3 | ||
| GO:0071157 | Negative regulation of cell cycle arrest | 6.31E−06 | MDM2 | ||
| GO:0043542 | Endothelial cell migration | 8.74E−06 | CYP1B1, ID1, HSPB1, PTK2 | ||
| GO:0007178 | Transmembrane receptor protein serine/threonine kinase signaling pathway | 7.25E−05 | ACVR1, BMPR1B, FURIN, GDF15, ID1, SMAD1, TGFBR3 | ||
| GO:0055108 | Golgi to transport vesicle transport | 0.0001783 | EXOC4 | ||
| GO:0046620 | Regulation of growth | 0.0001783 | NRG1, PTK2, SERP1 | ||
| GO:0051640 | Organelle localization | 0.0005195 | CDC42, COPA, GPSM2, MEF2A, MLPH, MYO5A PTK2, SAR1B | ||
| GO:0001525 | Angiogenesis | 0.0006979 | ACVR1, CEACAM1, CYP1B1, FN1, HSPB1, HSPG2, ID1, NAA15, PGF, SLC12A6 | ||
| GO:0010721 | Negative regulation of cell development | 0.0012465 | ACVR1, CEACAM1, CYP1B1, FN1, HSPB1, HSPG2, ID1, NAA15, PGF, SLC12A6 | ||
| GO:0030509 | Bone morphogenic protein (BMP) signaling pathway | 0.0028114 | ACVR1, BMPR1B, ID1, SMAD1, SMAD5, TGFBR3 | ||
| GO:0030174 | Regulation of DNA-dependent DNA replication initiation | 0.0044184 | CDT1, CIZ1 | ||
| GO:0000226 | Microtubule cytoskeleton organization | 0.0046760 | BLOC1S2, CCDC88B, CCDC88C, CEP250, CHD3, GPSM2, HAUS7, KIF23, MARK4, OFD1, PRC1, PTK2, SPC25 | ||
| GO:0022604 | Regulation of cell morphogenesis | 0.0051651 | CDC42EP1, CDKL5, FN1, LARP4, NOTCH1, PLXNB2, PTK2, RUFY3, SEMA3A, SEMA3F, SMAD1, XYLT1 | ||
| GO:0031344 | Regulation of cell projection organization | 0.0070184 | CDC42, CDC42EP1, CDKL5PLXNB2, PTK2, RUFY3, SEMA3A, SEMA3F, SMAD1, XYLT1 | ||
| GO:0007021 | Tubulin complex assembly | 0.0076473 | TBCA | ||
| GO:0018106 | Peptidyl-histidine phosphorylation | 0.0084104 | PDK1, PDK2 | ||
| GO:0030070 | Insulin processing | 0.0086510 | CPE | ||
|
| |||||
| GO:0045254 | Pyruvate dehydrogenase complex | 8.35E−05 | PDK1, PDK2 | ||
| GO:0005925 | Focal adhesion(Cell-substrate adherens junction) | 0.0010309 | PDLIM2, PTK2, TENC1 | ||
| GO:0048179 | Activin receptor complex | 0.0021545 | ACVR1 | ||
| GO:0000015 | Phosphopyruvate hydratase complex | 0.0034055 | ENO3 | ||
Figure 3GOEAST graphical output of enriched GO terms in molecular function ontology for IR-induced transcripts from radioresistant A549 cells.
Each box has GO terms labeled by its GO ID, term definition and detailed information representing ‘q/m|t/k (p-value)’. q is the number of genes associated with the listed GO ID (directly or indirectly) in our data set, m is the number of genes associated with the listed GO ID (directly or indirectly) on the selected platform, k is the total number of genes in our data set, t is the total number of genes on the selected platform, and p-value represent significance of the enrichment in the data set of the listed GO ID with hypergeometric distribution. Branches of the GO hierarchical tree without significantly enriched GO terms are not presented. The degree of color saturation of each box is positively associated with the enrichment significance of the corresponding GO term. Significantly enriched GO terms are indicated in yellow boxes. Insignificant GO terms within the hierarchical tree are shown as white boxes. Arrows show correlations between different GO terms. Red arrows reveal relationships between two enriched GO terms, black solid arrows reveal relationships between enriched and unenriched terms, and black dashed arrows reveal relationships between two unenriched GO terms.
Top-associated biofunctions and canonical pathways by IPA.
| Biofunctions - Diseases and disorders | p-value (<0.01) | #Molecules | |
| Cancer | 9.08E−04–2.32E−02 | 193 | |
| Gastrointestinal disease | 9.08E−04–2.35E−02 | 209 | |
| Genetic disorder | 1.15E−03–2.35E−02 | 107 | |
| Immunological disease | 3.37E−03–2.15E−02 | 21 | |
| Inflammatory response | 5.67E−03–1.58E−02 | 14 | |
| Connective tissue disorder | 6.58E−03–8.6E−03 | 7 | |
| Inflammatory disease | 1.07E−02–2.35E−02 | 65 | |
|
| |||
| Cell cycle | 1.79E−06–2.52E−02 | 71 | |
| Cellular assembly and organization | 4.48E−05–2.51E−02 | 90 | |
| Cell-To-Cell signaling and interaction | 7.09E−05–2.51E−02 | 45 | |
| DNA replication, recombination and repair | 1.51E−04–1.85E−02 | 65 | |
| Cell death | 3.03E−04–2.51E−02 | 109 | |
| Cellular development | 3.45E−04–2.45E−02 | 89 | |
| Cell morphology | 3.83E−04–2.25E−02 | 58 | |
| Molecular transport | 5.21E−04–2.46E−02 | 42 | |
| Cellular movement | 7.18E−04–2.51E−02 | 51 | |
| Cellular growth and proliferation | 7.77E−04–2.45E−02 | 173 | |
|
|
|
|
|
| Small cell lung cancer signaling | 3.20E+00 | 1.01E−01 | 9 |
| p53 signaling | 2.92E+00 | 1.04E−01 | 10 |
| EIF2 signaling | 2.84E+00 | 7.54E−02 | 15 |
| Molecular mechanisms of cancer | 2.53E+00 | 5.80E−02 | 22 |
| Aryl hydrocarbon receptor signaling | 2.16E+00 | 6.92E−02 | 11 |
IPA network analysis of radioresponsive genes in radioresistant A549 cells.
| Score | Number of focus genes | Top functions | Hub genes | Interacting partners |
| 38 | 28 | Cell death, Post-translational | MDM2 | TBCA, SMAD1 |
| modification, Protein folding | MYC | FASTKD2, HEATR1, ICA1, PGAP1, POLR3D, RBPJ, SNRPE, TLE4, XRCC | ||
| NOTCH1 | ID1, MYC, RBPJ, SMAD1 | |||
| SMAD1 | ICK, ID1, MDM2, MKL2, NOTCH1, SUV39H2 | |||
| 37 | 26 | Cancer, Cellular development, Connective tissue development and function | NFKB2 | CARD8, DOK3, E2F7, EDA2R, ERAP2, FAM46A, HIVEP1, MAP3K, PDLIM2,PPM1D, RNF19B, RNF25, TGFBR3, TRAF4 |
| SMAD5 | ACVR1 | |||
| 37 | 26 | Cell cycle, Cellular development, Hematological | AR | ATRX, NFKB2, RREB1, SLC45A3 |
| system development and | CDC42 | CDC42EP1, COPA | ||
| function | CDKN1A | AR, ATRX, CIZ1, DSE, KIAA0101, KLf16, NFKB2, PEX2, WHSC2 | ||
| DLG4 | CDKL5, SNX24, TUBB2B | |||
| NFKB2 | AR, CDKN1A, PSMD7, TUBB2B | |||
| 35 | 25 | Reproductive system | CAMK2D | ACTB, MYO5A |
| development and function, Drug metabolism, Endocrine system development and function | IFIT3 | MAVS | ||
| 21 | 20 | Lipid metabolism, Small molecule biochemistry, Cellular | MEF2A | ENO3, MEF2A, MYOCD, SLC2A4RG |
| development | MYOCD | MEF2A, ZNF354A | ||
| COX-2 | AGER, IGFBP7, MEF2A, TRAF1, VCAN | |||
| TRAF1 | COX-2, ZMAT3 | |||
| 19 | 20 | Repair, Cell death, DNA | BID | FAS, H2AFX, HSPA1A/1B |
| replication, Recombination, Cell | PTK2 | FAS | ||
| morphology | EIF2AK2 | DNAJC3, HSPA1A/1B | ||
| 17 | 16 | Cell-To-Cell signaling and interaction, Hematological system development and function, Immune cell trafficking | XPC | DDB2, KIN |
The score provides the networks a measure of how accurate the focus genes are matched. The assessment is based on the number of focus genes and network size. For details, refer to the following web site (Ingenuity Systems Pathway Analysis, http://www.ingenuity.com).
The assignment of functions to a network is based in literature stored in the IPA Knowledge Base.
Hub genes were selected in the basis of at least three interactions with differently expressed genes.
Interacting partners are the genes that served for identification of respective Hub genes.
Figure 4The top three ranked networks identified by IPA from the entire transcripts of IR-induced radioresistant A549 cells.
(A) Network for cell death, post-translational modification, and protein folding (score: 38). (B) Network for cellular development, connective tissue development and function, and cancer (score: 37). (C) Network for cell cycle, cellular development, and hematological system development and function (score: 37). Networks are displayed graphically as nodes (genes/gene products) and edges (biological relationships between the nodes). Intensity of the node color indicates the degree of regulation (red: up-regulation, green: down-regulation, white: not differentially expressed but related to this network).
Figure 5Accurate validation of our RNA-seq data.
(A) Correlation of differential expression between RNA-seq and real-time RT-PCR. The log2 ratios were generated by comparing expression levels in irradiated to non-irradiated radioresistant A549 cells. (B) Suggestion of gene expression-based putative biomarkers of radioresistance in NSCLC cells. Amplification of the GAPDH fragment in PCR was used as control. The results were confirmed by three independent experiments. Data was presented as mean ± standard deviation (SD) and analyzed using the one-way ANOVA on ranked data, followed by a Tukey's honestly significant difference test and the two-way ANOVA on ranked data, followed by a Bonferroni post test using Prism 4 (GraphPad Software, San Diego, CA). *p-value <0.05; irradiated cells vs. control cells, **p-value <0.01; irradiated cells vs. control cells, ***p-value <0.001; irradiated cells vs. control cells.
Figure 6Protein expression of candidate genes for radioresistance-associating factors in NSCLC cells.
IR-altered expression of Sestrin2, TRAF4, p21, COX-2 and FDXR was assayed by western blot analysis. The results were confirmed by three independent experiments.